Connect with our qualified team to learn more about Richter-Helm´s capabilities. Richter-Helm BioLogics will be present at the following conferences:


  • Nucleic Acids, February 1-3, 2021

  • Bio Europe Spring, March 22-25, 2021

  • German Corona Showcase, April 28-30 2021

  • Bio Digital, June 10-11 & 14-17, 2021

  • BioProduction (Part of CPhI Europe), Milan, August 31- September 2, 2021

  • Bio Europe, October 2021

  • Festival of Biologics, Basel, October 2021


Contact us to arrange a virtual meeting or a telephone conference.






10. March 2021

The NDR reports on the important role of Richter-Helm BioLogics as a Germany-based manufacturer of a DNA vaccine to support the Pharma industry and the fight against COVID-19. See and read more about our contribution to the fight against Corona.


15. February 2021

Dr. Kai Pohlmeyer, Managing Director of Richter-Helm BioLogics in an interview with WIRTSCHAFTSFORUM on the subject "Hoffnungsträger aus Hamburg" where Dr. Pohlmeyer is talking about Richter-Helm´s involvment in the production of vaccines against COVID-19. Learn more about Richter-Helm and how Richter-Helm supports the Pharma industry.

For a pdf version click here.


4. December 2020

Kommt der nächste Corona-Impfstoff aus Bovenau? – Quelle: ©2020

The Schleswig-Holsteinische Landeszeitung reports on Richter-Helm and its role as a manufacturer of a Corona vaccine in their article "Kommt der nächste Corona-Impfstoff aus Bovenau?".

For a pdf version click here.


4. November 2020

Learn more about Richter-Helm and our success story in "Erfolg durch Flexibilität" published in Transkript.


28. October 2020

Upcoming WEBINAR: "Corona Vaccine - Impact of Nanotechnology" 

Richter-Helm invites you to register for this Free-Access-Online-Symposium on November 24, 2020, 2 PM CET. At 3:35 PM CET Richter-Helm will give an exciting overview on „Covid-19, microbial manufacturing options for vaccines and treatments“.

Register today!


19. May 2020

The Veeva Vault Quality Management System is implemented at Richter-Helm as an electronic and cloud-based workflowmanagementsystem for our QA-processes.


30. April 2020

INOVIO and Richter-Helm BioLogics will expand existing DNA manufacturing agreement to support large-scale manufacturing of INO-4800

Richter-Helm BioLogics GmbH & Co. KG and Inovio Pharmaceuticals Inc. announced in a Press Release published 30. April 2020 their collaboration to manufacture Inovio´s INO-4800 DNA vaccine candidate that is targeted against the novel coronavirus (SARS-CoV-2).

“We at Richter-Helm will mobilize all our resources to ensure sufficient supply of late-stage clinical and commercial batches of INO-4800 and contribute to the fight against the deadly COVID-19 pandemic.” said Richter-Helm BioLogics’ Managing Director Dr. Kai Pohlmeyer.